Brain Cancer Cancer Malignant neoplasm of brain
Conditions
Interventions
Current interventions as of 22/08/2019:
Study participants (previously untreated glioblastoma patients for resection/debulking surgery) will undergo a CEST-MRI scan and ASL Perfusion MRI scan in addi
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Participant is willing, capable of cooperating with the protocol and able to give informed consent for participation in the study 2. Male or female, aged 18 years or above 3. Diagnosed with glioblastoma and scheduled for neurosurgical resection or debulking
Exclusion criteria
Exclusion criteria: Current exclusion criteria as of 16/02/2018: 1. Intolerant of MRI brain (for example: claustrophobia) 2. MRI brain contraindicated (for example: implanted electric and electronic devices, heart pacemakers, insulin pumps, implanted hearing aids, neurostimulators, intracranial metal clips, metallic bodies in the eye) 3. Neoadjuvant chemotherapy/radiotherapy treatment for glioblastoma which would interfere with the interpretation of trial results 4. Pregnancy 5. Other psychological, social or medical condition that the investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results Previous exclusion criteria: 1. Intolerant of MRI brain (for example: claustrophobia) 2. MRI brain contraindicated (for example: implanted electric and electronic devices, heart pacemakers, insulin pumps, implanted hearing aids, neurostimulators, intracranial metal clips, metallic bodies in the eye) 3. Prior treatment for glioblastoma 4. Pregnancy 5. Other psychological, social or medical condition that the investigator considers would make the patient a poor trial candidate or could interfere with protocol compliance or the interpretation of trial results
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pH-weighted CEST MRI signal, assessed using amide proton transfer ratio analysis, taken at the patient’s imaging visit | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 22/08/2019: 1. Protein levels obtained from tissue-based assay using biopsies obtained on the surgery date 2. pH levels obtained from tissue-based assay using biopsies obtained on the surgery date 3. Hypoxia markers obtained from immunohistochemistry using biopsies obtained on the surgery date 4. Cerebral blood flow and bolus arrival time from ASL MRI perfusion scan, taken at the patient’s imaging visit 5. Correlation of tumour metabolite levels and functional genetic pathway expression with CEST-MRI imaging signal Previous secondary outcome measures: 1. Protein levels obtained from tissue-based assay using biopsies obtained on the surgery date 2. pH levels obtained from tissue-based assay using biopsies obtained on the surgery date 3. Hypoxia markers obtained from immunohistochemistry using biopsies obtained on the surgery date 4. Cerebral blood flow and bolus arrival time from ASL MRI perfusion scan, taken at the patient’s imaging visit | — |
Countries
England, United Kingdom
Outcome results
None listed